Sequential analysis of chromosome aberrations in multiple myeloma during disease progression

Clinical Lymphoma and Myeloma

Volumn 7, Issue 4, 2007, Pages 280-285

  Ka, Lung Wu ^a   Beverloo, Berna ^a   Velthuizen, Sandra J C M ^a   Sonneveld, Pieter ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Chromosome 1; Clonal evolution; Cytogenetics; Fluorescence in situ hybridization

Indexed keywords

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CANCER GROWTH; CANCER STAGING; CHROMOSOME 17; CHROMOSOME 1P; CHROMOSOME 1Q; CHROMOSOME 8; CHROMOSOME ABERRATION; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION 1; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOGENETICS; DIPLOIDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE DELETION; GENE FREQUENCY; GENE LOCUS; GENETIC DISORDER; HUMAN; HUMAN TISSUE; KARYOTYPING; LONGITUDINAL STUDY; MALE; MULTIPLE MYELOMA; SEQUENCE ANALYSIS; STRUCTURAL CHROMOSOME ABERRATION;

EID: 33947154360     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2007.n.003     Document Type: Article

References (40)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351:1860-1873.
2. Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004; 64:1546-1558.
3. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998; 91:3-21.
4. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002; 2:175-187.
5. Avet-Loiseau H, Daviet A, Brigaudeau C, et al. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematologique. Blood 2001; 97:822-825.
6. Fonseca R, Debes-Marun CS, Picken EB, et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood 2003; 102:2562-2567.
7. Shou Y, Martelli ML, Gabrea A, et al. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci U S A 2000; 97:228-233.
8. Avet-Loiseau H, Gerson F, Magrangeas F, et al. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood 2001; 98:3082-3086.
9. Avet-Loiseau H, Facon T, Grosbois B, et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 2002; 99:2185-2191.
10. Lai JL, Zandecki M, Mary JY, et al. Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. Blood 1995; 85:2490-2497.
11. Zandecki M, Lai JL, Facon T. Multiple myeloma: almost all patients are cytogenetically abnormal. Br J Haematol 1996; 94:217-227.
12. Dewald GW, Kyle RA, Hicks GA, et al. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 1985; 66:380-390.
13. Sawyer JR, Waldron JA, Jagannath S, et al. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 1995; 82:41-49.
14. Calasanz MJ, Cigudosa JC, Odero MD, et al. Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: primary breakpoints and clinical correlations. Gene Chromosome Canc 1997; 18:84-93.
15. Drach J, Schuster J, Nowotny H, et al. Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization. Cancer Res 1995; 55:3854-3859.
16. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36:842-854.
17. Shaffer LG, Tommerup N, eds. ISCN (2005): An International System for Human Cytogenetic Nomenclature. Tokyo, Japan: Karger; 2005.
18. Weh HJ, Gutensohn K, Selbach J, et al. Karyotype in multiple myeloma and plasma cell leukaemia. Eur J Cancer 1993; 29A:1269-1273.
19. Nilsson T, Hoglund M, Lenhoff S, et al. A pooled analysis of karyotypic patterns, breakpoints and imbalances in 783 cytogenetically abnormal multiple myelomas reveals frequently involved chromosome segments as well as significant age- and sex-related differences. Br J Haematol 2003; 120:960-969.
20. Liebisch P, Viardot A, Bassermann N, et al. Value of comparative genomic hybridization and fluorescence in situ hybridization for molecular diagnostics in multiple myeloma. Br J Haematol 2003; 122:193-201.
21. Gutierrez NC, Garcia JL, Hernandez JM, et al. Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma. Blood 2004; 104:2661-2666.
22. Cremer FW, Bila J, Buck I, et al. Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics. Genes Chromosomes Cancer 2005; 44:194-203.
23. Sawyer JR, Tricot G, Mattox S, et al. Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin. Blood 1998; 91:1732-1741.
24. Le Baccon P, Leroux D, Dascalescu C, et al. Novel evidence of a role for chromosome 1 pericentric heterochromatin in the pathogenesis of B-cell lymphoma and multiple myeloma. Gene Chromosome Canc 2001; 32:250-264.
25. O'Shaughnessy J. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma. Hematology 2005; 10(suppl 1):117-126.
26. Inoue J, Otsuki T, Hirasawa A, et al. Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma. Am J Pathol 2004; 165:71-81.
27. Willis TG, Zalcberg IR, Coignet LJ, et al. Molecular cloning of translocation t(1;14)(q21;q32) defines a novel gene (BCL9) at chromosome 1q21. Blood 1998; 91:1873-1881.
28. Hatzivassiliou G, Miller I, Takizawa J, et al. IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy. Immunity 2001; 14:277-289.
29. Debes-Marun CS, Dewald GW, Bryant S, et al. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 2003; 17:427-436.
30. Nakagawa Y, Sawanobori M, Amaya H, et al. Clinical implications of abnormalities of chromosomes 1 and 13 in multiple myeloma. Acta Haematol 2003; 109:129-136.
31. Panani AD, Ferti AD, Papaxoinis C, et al. Cytogenetic data as a prognostic factor in multiple myeloma patients: involvement of 1p12 region an adverse prognostic factor. Anticancer Res 2004; 24:4141-4146.
32. Hanamura I, Stewart JP, Huang Y, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 2006; 108:1724-1732.
33. Smadja NV, Fruchart C, Isnard F, et al. Chromosomal analysis in multiple myeloma: Cytogenetic evidence of two different diseases. Leukemia 1998; 12:960-969.
34. Smadja NV, Leroux D, Soulier J, et al. Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases. Gene Chromosome Canc 2003; 38:234-239.
35. Fonseca R, Bailey RJ, Ahmann GJ, et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 2002; 100:1417-1424.
36. Kaufmann H, Ackermann J, Baldia C, et al. Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma. Leukemia 2004; 18:1879-1882.
37. Chng WJ, Winkler JM, Greipp PR, et al. Ploidy status rarely changes in myeloma patients at disease progression. Leuk Res 2006; 30:266-271.
38. Dewald GW, Therneau T, Larson D, et al. Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood 2005; 106:3553-3558.
39. Fonseca R, Harrington D, Oken MM, et al. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta 13) in multiple myeloma: an eastern cooperative oncology group study. Cancer Res 2002; 62:715-720.
40. Tricot G, Barlogie B, Jagannath S, et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995; 86:4250-4256.